Dichotomous effect of BAFF:inducing IL-35 production by regulatory T cells

doi:10.3969/j.issn.1006-7795.2017.05.002

Abstract

Abstract: Objective The purpose of this study was to determine whether B cell activation factor of the tumor necrosis factor (TNF) family (BAFF) has an effect on the production of interleukin-35 (IL-35) by regulatory T cells (Tregs), further identifying the dichotomous regulator of BAFF on immune responses in systemic lupus erythematosus (SLE). Methods Splenic CD4⁺ CD25⁺ T cells were sorted by magnetic isolation and stimulated with BAFF. The production of IL-35 was determined by flow cytometry and quantitative RT-PCR. Furthermore, the frequency of IL-35 producing Tregs in spleen from wild-type (WT) controls, MRL-Fas^lpr/lpr mice and anti-BAFF protein treated MRL-Fas^lpr/lpr mice was also analyzed by flow cytometry. Results We found that BAFF could promote Tregs to produce IL-35 in vitro. Flow cytometric analysis showed that the frequency of IL-35 producing Tregs was much higher in spleen of MRL-Fas^lpr/lpr mice which have increased serum level of BAFF compared with those in WT controls. Whereas anti-BAFF treatment weakened this effect. Conclusion In the pathogenesis of SLE, BAFF is not only a key pathogenic factor but also has immunosuppressive effect by promoting Tregs to produce IL-35.

Key words: systemic lupus erythematosus (SLE), B cell activation factor of the tumor necrosis factor family (BAFF), regulatory T cells, interleukin-35 (IL-35)

CLC Number:

R751

Zhang Yamin, Wang Ruiyun, Li Jun, Tao Juan, Tu Yating. Dichotomous effect of BAFF:inducing IL-35 production by regulatory T cells[J]. Journal of Capital Medical University, 2017, 38(5): 640-644.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.05.002

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I5/640

References

[1] Tsokos G C, Lo M S, Costa Reis P, et al. New insights into the immunopathogenesis of systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2016,12(12):716-730.
[2] Kaul A, Gordon C, Crow M K, et al. Systemic lupus erythematosus[J].Nat Rev Dis Primers, 2016,2:16039.
[3] Vincent F B, Saulep-Easton D,Figgett W A, et al. The BAFF/APRIL system:emerging functions beyond B cell biology and autoimmunity[J]. Cytokine Growth Factor Rev, 2013,24(3):203-215.
[4] Vincent F B, Morand E F, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis[J]. Nat Rev Rheumatol, 2014,10(6):365-373.
[5] Yang M, Sun L, Wang S, et al. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells[J]. J Immunol, 2010,184(7):3321-3325.
[6] Saulep-Easton D, Vincent F B, Quah P S, et al. The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells[J]. Leukemia, 2016,30(1):163-172.
[7] Chen M, Lin X, Liu Y, et al. The function of BAFF on T helper cells in autoimmunity[J]. Cytokine Growth Factor Rev, 2014,25(3):301-305.
[8] Huard B, Arlettaz L, Ambrose C,et al. BAFF production by antigen presenting cells provides T cell co-stimulation[J]. Int Immunol, 2004,16(3):467-475.
[9] Coquery C M, Loo W M, Wade N S, et al. BAFF regulates T follicular helper cells and affects their accumulation and IFN-γ production in autoimmunity[J]. Arthritis Rheumatol, 2015,67(3):773-784.
[10] Walters S, Webster K E, Sutherland A, et al. Increased CD4⁺ Foxp3⁺ T cells in BAFF-transgenic mice suppress T cell effector responses[J]. J Immunol, 2009,182(2):793-801.
[11] Sawant D V, Hamilton K, Vignali D A. Interleukin-35:expanding its job profile[J]. J Interferon Cytokine Res, 2015,35(7):499-512.
[12] Collison L W, Workman C J, Kuo T T, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007,450(7169):566-569.
[13] Collison L W, Chaturvedi V, Henderson A L, et al. IL-35 mediated induction of a potent regulatory T cell population[J]. Nat Immunol, 2010,11(12):1093-1101.
[14] Cai Z, Wong C K, Dong J, et al. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice[J]. Clin Exp Immunol, 2015,181(2):253-266.
[15] Zhang Y, Li J, Zhang Y M, et al. Effect of TACI signaling on humoral immunity and autoimmune diseases[J]. J Immunol Res, 2015,2015:247426.
[16] Ng L G, Sutherland A P, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells[J]. J Immunol, 2004,173(2):807-817.
[17] Sutherland A P, Ng L G, Fletcher C A, et al. BAFF augments certain Th1-associated inflammatory responses[J]. J Immunol, 2005,174(9):5537-5544.
[18] Scapini P, Hu Y, Chu C L, et al. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice[J]. J Exp Med, 2010,207(8):1757-1773.
[19] Zhou X, Xia Z, Lan Q, et al. BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis[J]. PLoS One, 2011,6(8):e23629.
[20] Gross J A, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease[J]. Nature, 2000,404(6781):995-999.
[21] Ding H, Wang L, Wu X, et al. Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice[J]. J Cell Mol Med, 2010,14(6B):1717-1725.
[22] Furie R, Petri M, Zamani O, et al. A phase Ⅲ, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2011,63(12):3918-3930.